Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 195 of the 196 references it cites were found in a registry or an index; 105 of the 183 sources its claims cite were checked for support.

Targeting macrophages in liver fibrosis

Open access
González del Barrio, Lydia, Ipsen, David H., Pfister, Dominik R., Hancz, Dora, Scott, Charlotte L. · 2026 · Frontiers in Immunology

Abstract

Fibrosis results from excessive deposition of extracellular matrix (ECM) components following tissue injury. While initially protective, chronic injury drives pathological ECM accumulation, tissue remodeling, and organ dysfunction. In the liver, fibrosis represents a common endpoint of chronic diseases, including metabolic dysfunction–associated steatotic liver disease (MASLD). Macrophages are central players of the fibrotic hepatic niche, modulating inflammatory signals, immune regulation, and tissue repair. Recent advances demonstrate that hepatic macrophages form a heterogeneous and highly dynamic compartment, adopting diverse activation states that extend far beyond the classical M1/M2 paradigm. Importantly, liver fibrosis is now recognized as a potentially reversible process, with resolution being closely linked to the reprogramming of macrophages towards restorative phenotypes characterized by enhanced efferocytosis, reduced pro-inflammatory signaling, and increased matrix degradation capacity. As a result, efforts to design macrophage-based therapeutic strategies are shifting from non-specific approaches such as inhibition of monocyte recruitment towards approaches that actively promote pro-resolution programs, including targeted in situ reprogramming and more recently cell-based macrophage therapies. In this review, we summarize the hepatic macrophage landscape in the fibrotic liver and discuss current opportunities and challenges in developing macrophage-based anti-fibrotic therapies.

Overview

CoChat Summary

## TL;DR

This is a review of how hepatic macrophage biology can be leveraged for anti-fibrotic therapy in liver fibrosis. It argues that because macrophages are heterogeneous, plastic, and sometimes reparative, the field is moving away from broad monocyte-recruitment blockade toward targeted reprogramming and cell-based approaches.

## Key findings

  • Liver fibrosis is a major global problem: the paper states liver pathologies contribute to more than 2 million deaths annually, and MASLD prevalence has been estimated at 30.05% in adults (20+) in one meta-analysis, 14.4% age-adjusted / 16.1% global in a 2023 analysis, with projections of 1.8 billion cases by 2050.
  • Hepatic macrophages are central to both fibrogenesis and resolution: in the liver they comprise about 70% of immune cells, and the paper emphasizes that macrophages can drive either fibrogenic or fibrolytic processes depending on context.
  • Broad recruitment blockade has mixed clinical results: in murine models, CCR2 deletion reduced monocyte infiltration and fibrosis; cenicriviroc showed collagen deposition reduction preclinically and improvement in phase IIb, but phase III failed to show significant fibrosis improvement without worsening steatohepatitis in the first year.
  • The review highlights promising but still early approaches: dexamethasone-loaded nanoparticles reduced HSC activation and collagen deposition in a chronic liver injury mouse model, but failed in rat models with increased collagen deposition; MATCH phase I macrophage infusions were safe and well-tolerated, but phase II did not improve MELD at 90 days, although later follow-up suggested fewer liver-related adverse effects and improved survival.

## Methods

  • This is a narrative review, not an original experimental study; it synthesizes animal and human studies on hepatic macrophages and liver fibrosis.
  • The paper draws mainly on murine preclinical models (including CCl4, bile duct ligation, and diet-induced MASH models) and incorporates human data where available.
  • Its analysis is a conceptual/thematic synthesis of macrophage heterogeneity, liver macrophage niches, and therapeutic strategies: indirect modulation, recruitment blockade, in situ reprogramming, and cell-based therapies.

## Limitations

  • The paper explicitly says translation is limited by the field’s reliance on animal, especially mouse, models, with many therapies showing strong preclinical effects that have failed to translate clinically.
  • It also states that the understanding of macrophage fate is incomplete, and that comparable datasets from patients with fibrosis resolution are not currently available; this makes human translation difficult.
  • Evident from the text: the article is a review, so its conclusions depend on the quality and comparability of the cited studies rather than on new primary data.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fimmu.2026.1835489

Cites

195 of 196 references verified0 citation errors · 1 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Conceptual analogy of macrophage activation as a light system. Macrophage activation in the fibrotic liver is a continuous, multidimensional spectrum rather than a binary M1/M2 switch, and this plasticity should be taken into account when designing macrophage-targeted therapies. (A) The traditional M1/M2 nomenclature represents macrophages as a binary switch, either “on” (M1, pro-inflammatory) or “off” (M2, anti-inflammatory). (B) Modern single-cell and functional studies show macrophage polarization is not binary, but rather a continuous spectrum of activation states better represented by a dimmable, color-changing light bulb: brightness reflects the intensity of activation, while color reflects the quality of responses. (C) Within fibrotic tissues such as the liver, macrophages can occupy different positions along this spectrum depending on microenvironmental signals.
Figure 1 Conceptual analogy of macrophage activation as a light system. Macrophage activation in the fibrotic liver is a continuous, multidimensional spectrum rather than a binary M1/M2 switch, and this plasticity should be taken into account when designing macrophage-targeted therapies. (A) The traditional M1/M2 nomenclature represents macrophages as a binary switch, either “on” (M1, pro-inflammatory) or “off” (M2, anti-inflammatory). (B) Modern single-cell and functional studies show macrophage polarization is not binary, but rather a continuous spectrum of activation states better represented by a dimmable, color-changing light bulb: brightness reflects the intensity of activation, while color reflects the quality of responses. (C) Within fibrotic tissues such as the liver, macrophages can occupy different positions along this spectrum depending on microenvironmental signals.CC BY · PubMed Central
Figure 2 Cellular and molecular pathways in liver fibrosis. Liver fibrosis results from a complex multicellular cascade in which macrophages are proposed to be a central orchestrator, playing a dual role at both promoting and resolving fibrosis, depending on the context. Chronic liver injury caused by metabolic dysfunction–associated steatohepatitis (MASH)/obesity, viral hepatitis, prolonged toxin exposure, or excessive alcohol consumption results in hepatocyte damage and death. Injured hepatocytes release damage-associated molecular patterns (DAMPs) and reactive oxygen species (ROS), which activate resident Kupffer cells (KCs) and promote the recruitment of circulating monocytes that differentiate into monocyte-derived macrophages (MDMs) and monocyte-derived KCs (MoKCs), expanding the hepatic macrophage pool. In parallel, dead hepatocytes are phagocytosed by macrophages, which leads to either their activation and/or their death, depending on the context. Activated macrophages secrete pro-inflammatory and pro-fibrogenic mediators, including TNF-α, IL-1β, TGF-β, and PDGF, which drive the activation of quiescent hepatic stellate cells (HSCs) into collagen-producing activated HSCs (aHSCs). aHSCs are the principal source of extracellular matrix (ECM) proteins, leading to collagen deposition. Furthermore, aHSCs may undergo apoptosis, which will be cleared by KCs, again leading to KC activation and/or death, which further drives the activation of HSCs, resulting in a perpetuating cycle. Crosstalk between macrophages, aHSCs, (activated) liver sinusoidal endothelial cells (LSECs), and other recruited immune cells, such as neutrophils, sustain immune activation and fibrogenesis, while macrophage-induced aHSC apoptosis and phagocytic clearance can contribute to fibrosis resolution. Ultimately, fibrosis severity is determined by the balance between extracellular matrix (ECM) deposition by aHSCs and ECM degradation mediated by matrix metalloproteinases (MMPs), which are neutralized by tissue inhibitors of metalloproteinases (TIMPs).
Figure 2 Cellular and molecular pathways in liver fibrosis. Liver fibrosis results from a complex multicellular cascade in which macrophages are proposed to be a central orchestrator, playing a dual role at both promoting and resolving fibrosis, depending on the context. Chronic liver injury caused by metabolic dysfunction–associated steatohepatitis (MASH)/obesity, viral hepatitis, prolonged toxin exposure, or excessive alcohol consumption results in hepatocyte damage and death. Injured hepatocytes release damage-associated molecular patterns (DAMPs) and reactive oxygen species (ROS), which activate resident Kupffer cells (KCs) and promote the recruitment of circulating monocytes that differentiate into monocyte-derived macrophages (MDMs) and monocyte-derived KCs (MoKCs), expanding the hepatic macrophage pool. In parallel, dead hepatocytes are phagocytosed by macrophages, which leads to either their activation and/or their death, depending on the context. Activated macrophages secrete pro-inflammatory and pro-fibrogenic mediators, including TNF-α, IL-1β, TGF-β, and PDGF, which drive the activation of quiescent hepatic stellate cells (HSCs) into collagen-producing activated HSCs (aHSCs). aHSCs are the principal source of extracellular matrix (ECM) proteins, leading to collagen deposition. Furthermore, aHSCs may undergo apoptosis, which will be cleared by KCs, again leading to KC activation and/or death, which further drives the activation of HSCs, resulting in a perpetuating cycle. Crosstalk between macrophages, aHSCs, (activated) liver sinusoidal endothelial cells (LSECs), and other recruited immune cells, such as neutrophils, sustain immune activation and fibrogenesis, while macrophage-induced aHSC apoptosis and phagocytic clearance can contribute to fibrosis resolution. Ultimately, fibrosis severity is determined by the balance between extracellular matrix (ECM) deposition by aHSCs and ECM degradation mediated by matrix metalloproteinases (MMPs), which are neutralized by tissue inhibitors of metalloproteinases (TIMPs).CC BY · PubMed Central
Figure 3 Remaining questions regarding LAM biology. Lipid-associated macrophage (LAM) biology remains incompletely understood. Fate-mapping tools and relevant human models are critically needed to resolve their pro vs anti-fibrotic roles, which will help to the development of future LAM-based therapeutic strategies. LAMs, also known as SAMs/NAMs, have been shown to be generated in the context of liver fibrosis, where they originate from recruited monocytes. These cells occupy a distinct niche from KCs, being located at zones of fibrosis. However, resident and monocyte-derived KCs can also acquire a LAM-like phenotype. Acquisition of the LAM/LAM-like phenotype has been shown to be, at least in part, dependent on the uptake and clearance of dying cells in the local microenvironment, suggesting that this may indeed reflect a conserved activation state of macrophages rather than a distinct subset. Interestingly, reanalysis of publicly available bulk RNA-seq data of monocytes entering the homeostatic liver and generating moKCs following depletion of their embryonic counterparts (25) has revealed that these cells can also temporarily acquire a LAM-like phenotype, whereby LAM-associated genes are upregulated in monocytes recruited to the liver (rec. monocytes, 1 day post KC depletion), compared with BM monocytes, and that this expression is maintained in the differentiating moKCs 3 days (D3) post KC deletion. By day 7, many of these genes have been downregulated to levels associated with embryonic KCs (KCs, D30), and this expression is maintained until at least 30 days post depletion (D30). The timing of this downregulation correlates with the acquisition of KC markers (D7) as previously described (25). This raises the question whether all BM monocytes transitioning into MDMs in the liver would go through a LAM intermediate stage or if this is associated only with a subset of MDMs? In line with this, the fate of LAMs during and following fibrosis resolution remains to be determined. Can LAMs exist in multiple flavours explaining data suggesting both pro and anti fibrotic roles for these cells? Moreover, while LAMs are no longer present in the liver upon return to homeostasis, it remains unclear if this is due to their death or differentiation into, for example, moKCs.
Figure 3 Remaining questions regarding LAM biology. Lipid-associated macrophage (LAM) biology remains incompletely understood. Fate-mapping tools and relevant human models are critically needed to resolve their pro vs anti-fibrotic roles, which will help to the development of future LAM-based therapeutic strategies. LAMs, also known as SAMs/NAMs, have been shown to be generated in the context of liver fibrosis, where they originate from recruited monocytes. These cells occupy a distinct niche from KCs, being located at zones of fibrosis. However, resident and monocyte-derived KCs can also acquire a LAM-like phenotype. Acquisition of the LAM/LAM-like phenotype has been shown to be, at least in part, dependent on the uptake and clearance of dying cells in the local microenvironment, suggesting that this may indeed reflect a conserved activation state of macrophages rather than a distinct subset. Interestingly, reanalysis of publicly available bulk RNA-seq data of monocytes entering the homeostatic liver and generating moKCs following depletion of their embryonic counterparts (25) has revealed that these cells can also temporarily acquire a LAM-like phenotype, whereby LAM-associated genes are upregulated in monocytes recruited to the liver (rec. monocytes, 1 day post KC depletion), compared with BM monocytes, and that this expression is maintained in the differentiating moKCs 3 days (D3) post KC deletion. By day 7, many of these genes have been downregulated to levels associated with embryonic KCs (KCs, D30), and this expression is maintained until at least 30 days post depletion (D30). The timing of this downregulation correlates with the acquisition of KC markers (D7) as previously described (25). This raises the question whether all BM monocytes transitioning into MDMs in the liver would go through a LAM intermediate stage or if this is associated only with a subset of MDMs? In line with this, the fate of LAMs during and following fibrosis resolution remains to be determined. Can LAMs exist in multiple flavours explaining data suggesting both pro and anti fibrotic roles for these cells? Moreover, while LAMs are no longer present in the liver upon return to homeostasis, it remains unclear if this is due to their death or differentiation into, for example, moKCs.CC BY · PubMed Central
Figure 4 Anti-fibrotic macrophage-based therapeutic approaches. Overview of current and emerging strategies to target macrophages for the treatment of liver fibrosis. Therapeutic approaches are grouped into four main categories. Indirect macrophage-modulating strategies aim to inhibit pro-fibrotic and inflammatory mediators or signalling pathways, such as cytokine production or inflammasome activation. Monocyte recruitment inhibition limits the influx of circulating monocytes into the injured liver, for example, through blockade of the CCL2-CCR2 axis. In situ macrophage reprogramming seeks to shift endogenous macrophages towards a pro-restorative phenotype using targeted delivery systems, such as loaded nanoparticles. Cell-based therapies involve the administration of autologous monocyte-derived macrophages or engineered induced pluripotent stem cell (iPSC)-derived macrophages to promote tissue repair and fibrosis resolution. To date, no macrophage-targeted strategies have achieved robust clinical efficacy. Future progress will likely require combining the distinct strategies.
Figure 4 Anti-fibrotic macrophage-based therapeutic approaches. Overview of current and emerging strategies to target macrophages for the treatment of liver fibrosis. Therapeutic approaches are grouped into four main categories. Indirect macrophage-modulating strategies aim to inhibit pro-fibrotic and inflammatory mediators or signalling pathways, such as cytokine production or inflammasome activation. Monocyte recruitment inhibition limits the influx of circulating monocytes into the injured liver, for example, through blockade of the CCL2-CCR2 axis. In situ macrophage reprogramming seeks to shift endogenous macrophages towards a pro-restorative phenotype using targeted delivery systems, such as loaded nanoparticles. Cell-based therapies involve the administration of autologous monocyte-derived macrophages or engineered induced pluripotent stem cell (iPSC)-derived macrophages to promote tissue repair and fibrosis resolution. To date, no macrophage-targeted strategies have achieved robust clinical efficacy. Future progress will likely require combining the distinct strategies.CC BY · PubMed Central

Verification

Claims the paper makes

57 Valid · 2 Not valid · 24 Not checked · 33 Own results and interpretations

56 more claims · 21 with their cited sources checked

Create a free account to see all 116 claims and to verify the 12 references still open.

See all claims — free account
  • It may state two separate claims as one. 49
  • Probably not a substantial claim. 12

Create a free account to see these claims.

Citations

Cites

Show all 194 references

Research works printed but not linked: 5

  1. Davies, 2013, Tissue-resident macrophages, Nat Immunol, 14, 10.1038/ni.2705 · DOI · Paper page
  2. Younossi, 2023, The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review, Hepatology, 77, 10.1097/HEP.0000000000000004 · DOI · Paper page
  3. Satdarshan, 2010, Gross and cellular anatomy of the liver, 2
  4. Anstee, 2024, Cenicriviroc lacked efficacy to treat liver fibrosis in nonalcoholic steatohepatitis: AURORA phase III randomized study, Clin Gastroenterol Hepatol, 22, 124, 10.1016/j.cgh.2023.04.003 · DOI · Paper page
  5. Harrison, 2020, Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials, J Hepatol, 73, 26, 10.1016/j.jhep.2020.02.027 · DOI · Paper page

Metadata

Authors
González del Barrio, L., Ipsen, D. H., Pfister, D. R., Hancz, D., & Scott, C. L.
Affiliations
  • Laboratory of Myeloid Cell Biology in Tissue Damage and Inflammation, VIB Center for Inflammation Research
  • Global Research, Novo Nordisk A/S
  • Ghent University (BE)
Corresponding author
Scott, Charlotte L.
Venue
Frontiers in Immunology
Published
2026-05-22
Volume
17
Pages
1835489-1835489
ISSN
1664-3224 (ISSN-L)
OpenAlex
W7162093433
Cited by
3
References
194
Citations by year
2026: 3
FWCI
3.70
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion, cc-by)
Funders
  • Fonds Wetenschappelijk Onderzoek (G0A9Z24N, G075923N)
  • Stichting Tegen Kanker
Topics
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Keywords
liver fibrosis, hepatic macrophages, macrophage heterogeneity, macrophage polarization, non-alcoholic fatty liver disease, extracellular matrix deposition, tissue remodeling, macrophage reprogramming, efferocytosis, antifibrotic therapy, monocyte recruitment
MeSH terms
Efferocytosis, Animals, Extracellular Matrix, Humans, Liver, Liver Cirrhosis, Macrophage Activation, Macrophages

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting macrophages in liver fibrosis. https://app.cochat.ai/papers/10.3389/fimmu.2026.1835489
The paper
González del Barrio, L., Ipsen, D. H., Pfister, D. R., Hancz, D., & Scott, C. L. (2026). Targeting macrophages in liver fibrosis. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1835489

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.